Prognostic significance of the Geriatric 8 score alone and included with genetic risk group in older adults with acute myeloid leukemia.

[1]  B. Cho,et al.  Geriatric assessment predicts non-fatal toxicities and survival for intensively treated older adults with AML. , 2022, Blood.

[2]  T. Yamauchi,et al.  Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B‐cell lymphoma , 2021, British journal of haematology.

[3]  H. Döhner,et al.  Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[5]  H. Kurita,et al.  Clinical significance of the G8 screening tool in elderly patients with oral squamous cell carcinoma , 2019, Clinical Oral Investigations.

[6]  Xiaomei Ma,et al.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.

[7]  A. Wei,et al.  Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[9]  M. Heuser,et al.  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome , 2018, Leukemia.

[10]  M. Sakurai,et al.  Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma , 2018, Annals of Hematology.

[11]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[12]  Chikashi Ishioka,et al.  The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study , 2017, PloS one.

[13]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[14]  C. Bloomfield,et al.  A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. , 2017, Blood advances.

[15]  H. Kantarjian,et al.  Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia , 2015, British journal of haematology.

[16]  S. Mathoulin-Pélissier,et al.  Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study , 2014, PloS one.

[17]  H. Wildiers,et al.  International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Nørgaard,et al.  Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study , 2014, Leukemia.

[19]  R. Stauder,et al.  The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy , 2014, Annals of Hematology.

[20]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[21]  P. Venugopal,et al.  Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. , 2012, The Lancet. Oncology.

[22]  H. Kantarjian,et al.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.

[23]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[24]  C. Schiffer.  "I am older, not elderly," said the patient with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[26]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  A. Wåhlin,et al.  Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia , 2001, British journal of haematology.

[28]  R. Clark,et al.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[29]  U. Maurer,et al.  High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. , 1997, Blood.

[30]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[31]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[32]  H. Wildiers,et al.  Performance of two geriatric screening tools in older patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.